Insmed Incorporated (INSM) News
Follow Insmed Incorporated (INSM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 42 public stories across 22 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
M
Insmed shares rise after revenue outlook raised
Insmed shares posted their biggest intraday gain in more than two months after the company raised its revenue outlook.
EARNINGS | Oct 29, 2026, 02:35 PM UTC
M
Insmed shares gain 14.7%
Insmed shares advanced 14.7%, according to the alert.
EQUITY | Oct 29, 2026, 02:33 PM UTC
M
Insmed shares jump 11.7% after Q3 revenue beat
INSMED SHARES JUMP 11.7% AFTER Q3 REVENUE BEAT
EQUITY | Oct 29, 2026, 01:36 PM UTC
M
Insmed Q3 Net Loss Narrows as Revenue Rises
Insmed reported a narrower net loss and higher revenue in the third quarter.
EQUITY | Oct 29, 2026, 12:52 PM UTC
M
Insmed Reports Third-Quarter Results, Raises 2026 Sales Guidance
Insmed reported a narrower year-over-year net loss and raised its 2026 sales outlook to $1.81 billion-$1.87 billion. Its ARIKAYCE revenue outlook is now $460 million-$470 million.
EQUITY | Oct 29, 2026, 11:33 AM UTC
M
Insmed Reports Q3 Revenue of $524.4 Million, Raises 2026 Guidance
Third-quarter 2026 revenue rose 268% year over year to $524.4 million; Insmed reported a net loss of $100.3 million, or $0.46 per share, and raised full-year revenue guidance for BRINSUPRI and ARIKAYCE.
EQUITY | Oct 29, 2026, 11:19 AM UTC
M
Insmed shares jump 20.1% premarket after Q3 revenue beat
EQUITY | Oct 29, 2026, 11:16 AM UTC
M
Insmed Q3 Revenue Beats Estimates, Raises Forecast
EQUITY | Oct 29, 2026, 11:13 AM UTC
L
Insmed launches BRINSUPRI tablets in Japan
Insmed launched BRINSUPRI 25 mg tablets (brensocatib hydrate) for non-cystic fibrosis bronchiectasis in Japan.
EQUITY | Oct 19, 2026, 11:00 AM UTC
H
Nasdaq 100 Hits Record, Brazil's EWZ Soars 13%: Stock Market Today
Wall Street posted modest gains at midday Monday, with the Nasdaq 100 hitting a record high on megacap tech strength even as the 10-year Treasury yield rose to 5.3%. President Donald Trump said Friday of the Iran war tha
LIVE | Oct 05, 2026, 04:53 PM UTC
H
Insmed Stock Slides — CFO Exit Date Set, 2026 Guidance Reaffirmed
Insmed Inc. (NASDAQ: INSM ) shares are trading lower by almost 7% on Monday as traders digest a CFO transition update alongside a slightly softer risk tone. Insmed CFO Transition and 2026 Guidance Reaffirmed Insmed said
LIVE | Oct 05, 2026, 03:59 PM UTC
H
Insmed shares are trading lower after the company reaffirmed its FY26 revenue guidance. Also, CFO Sara Bonstein will step down.
Insmed shares are trading lower after the company reaffirmed its FY26 revenue guidance. Also, CFO Sara Bonstein will step down.
LIVE | Oct 05, 2026, 01:15 PM UTC
H
Insmed Q2 2026 Earnings Call Transcript
Insmed (NASDAQ: INSM ) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. APIs provide real-time access to earnings call transcr
LIVE | Oct 05, 2026, 11:46 AM UTC
H
Insmed Reaffirms FY26 Revenue Guidance Of $1.25B-$1.40B For BRINSUPRI And $450M- $470M For ARIKAYCE
Reaffirms Full-Year 2026 Guidance As Insmed continues to build on its operational excellence and momentum, the Company reaffirms its full-year 2026 financial guidance of revenue in the range of $1.25 billion to $1.40 bil
LIVE | Oct 05, 2026, 11:07 AM UTC
L
Insmed Price Target Announced at $188.00/Share by Goldman Sachs
Ratings actions from Benzinga
NEWS | Sep 24, 2026, 01:51 PM UTC
M
FDA grants priority review to Insmed SNDA for Arikayce
FDA granted priority review to Insmed's SNDA for Arikayce to treat mac lung disease. The PDUFA target action date is January 28, 2027.
REGULATION | Sep 21, 2026, 12:23 PM UTC
M
FDA grants priority review to Insmed ARIKAYCE sNDA
FDA granted priority review to Insmed's supplemental new drug application (sNDA) for ARIKAYCE® (amikacin liposome inhalation suspension) to treat MAC lung disease. The Prescription Drug User Fee Act (PDUFA) target action
REGULATION | Sep 21, 2026, 11:00 AM UTC
L
INSM - Insmed Expands Community Impact During Fifth Annual Global Day of Good
INSM - Insmed Expands Community Impact During Fifth Annual Global Day of Good
NEWS | Sep 16, 2026, 11:02 AM UTC
L
Insmed Price Target Cut to $198.00/Share From $212.00 by Roth Capital
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 04:51 PM UTC
H
INSM: BRINSUPRI's blockbuster launch and robust pipeline set the stage for sustained, multi-year growth
BRINSUPRI's launch has exceeded expectations, with first-year revenue estimates of $1.25—$1.4 billion and peak sales guidance raised above $7 billion. Expansion into COPD/asthma comorbid populations and international mar
EARNINGS | Sep 14, 2026, 08:01 PM UTC
H
INSM: BRINSUPRI's blockbuster launch and expanding pipeline set the stage for sustained high growth
BRINSUPRI's launch has exceeded expectations, with first-year revenue projected at $1.25—$1.4 billion and peak sales guidance raised above $7 billion. Expansion into comorbid COPD and asthma populations, strong internati
EARNINGS | Sep 14, 2026, 07:38 PM UTC
L
Insmed Director Sold Shares Worth Over $3.1M
David R. Brennan, a Director, reported a direct sale of 25,000 shares of Common Stock at $124.00 per share on September 9, 2026. The total reported sale amount was $3,100,000. Following the transaction, Brennan directly
EQUITY | Sep 11, 2026, 08:12 PM UTC
H
Insmed raises peak sales guidance to $14 billion
Insmed (INSM) raised peak sales guidance to $14 billion, citing strong BRINSUPRI and TPIP performance and expanding indications. It expects profitability next year.
EARNINGS | Sep 09, 2026, 02:06 PM UTC
H
INSM raises peak sales guidance to $14 billion across three products
INSM raised peak sales guidance to $14 billion across three products. BRINSUPRI and TPIP revisions were driven by strong launch metrics and expanded indications, with BRINSUPRI launch outperforming analogs.
EARNINGS | Sep 09, 2026, 01:40 PM UTC
L
Insmed announces inducement awards under Nasdaq Rule 5635(c)(4)
Insmed Incorporated announced the granting of inducement awards under Nasdaq Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 11:00 AM UTC
L
Insmed reports inducement grants under NASDAQ Rule 5635(c)(4)
Insmed disclosed inducement grants under NASDAQ Listing Rule 5635(c)(4).
EQUITY | Sep 04, 2026, 11:00 AM UTC
H
INSM - Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspensi
INSM - Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congr
GEOPOLITICS | Sep 03, 2026, 11:01 AM UTC
L
Insmed set to present at September 2026 investor conferences
Insmed says it will present at September 2026 investor conferences, according to TradeXchange Newsdesk.
EQUITY | Aug 26, 2026, 11:01 AM UTC
M
INSM brensocatib approved in Japan for bronchiectasis
INSM says brinsupri (brensocatib) has been approved by Japan’s Ministry of Health, Labour and Welfare for patients with non-cystic fibrosis bronchiectasis.
REGULATION | Aug 24, 2026, 11:06 AM UTC
M
Insmed's Brinsupri wins Japan approval for bronchiectasis
Insmed says Japan's Ministry of Health, Labour and Welfare approved BRINSUPRI (brensocatib) for patients with non-cystic fibrosis bronchiectasis.
REGULATION | Aug 24, 2026, 11:00 AM UTC
H
Alnylam cuts 2026 Amvuttra revenue guidance
Alnylam Pharmaceuticals cuts full-year 2026 revenue guidance for its Amvuttra franchise after early demand was inflated by a rush of pent-up patients.
EARNINGS | Aug 20, 2026, 04:03 PM UTC
H
Crude Oil Gains 2%; Keurig Dr Pepper Earnings Top Views
U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 300 points on Thursday. The Dow traded down 0.63% to 54,005.27 while the NASDAQ fell 0.05% to 26,349.83. The S&P 500 also fell, dropp
EARNINGS | Aug 06, 2026, 04:04 PM UTC
H
Motorola Solutions Posts Upbeat Q2 Earnings, Joins Insmed, Diodes, Parker-Hannifin And Other Big Stocks Moving Higher On Thursday
U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Thursday. Shares of Motorola Solutions In c (NYSE: MSI ) rose sharply after the company reported better-than-expected second-quarter financial
EARNINGS | Aug 06, 2026, 02:01 PM UTC
H
Insmed Raises FY2026 Sales Guidance from $1.450B-$1.470B to $1.700B-$1.870B vs $1.705B Est
Insmed (NASDAQ: INSM ) raises FY2026 sales outlook from $1.450 billion-$1.470 billion to $1.700 billion-$1.870 billion vs $1.705 billion estimate.
EARNINGS | Aug 06, 2026, 11:07 AM UTC
L
INSM INSM - Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
INSM INSM - Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update
EQUITY | Aug 06, 2026, 11:01 AM UTC
L
Near 50dma resistance SRE FLO LVS CSGP MSFT AAL TMUS ALLY HAYW VICI BIRK RKT INSM Z CSCO NKE STWD ZG DIS ESAB
Near 50dma resistance SRE FLO LVS CSGP MSFT AAL TMUS ALLY HAYW VICI BIRK RKT INSM Z CSCO NKE STWD ZG DIS ESAB
EQUITY | Jul 28, 2026, 03:56 PM UTC
L
INSM new Outperform W/ $192 PT @ BMO
INSM new Outperform W/ $192 PT @ BMO
EQUITY | Jul 21, 2026, 11:14 AM UTC
L
INSM Insmed - tpip demonstrates sustained improvement and reduced mortality risk at 12 months - Tpip safe and well-tolerated with no new saf
INSM Insmed - tpip demonstrates sustained improvement and reduced mortality risk at 12 months - Tpip safe and well-tolerated with no new safety signals through month 12
EQUITY | Jul 16, 2026, 11:02 AM UTC
L
INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) i
INSM Insmed announces positive 12-month data from the ongoing open-label extension study of treprostinil palmitil inhalation powder (tpip) in patients with pulmonary arterial hypertension
EQUITY | Jul 16, 2026, 11:00 AM UTC
L
Insmed Insider Sold Shares Worth $1,256,084, According to a Recent SEC Filing
() -- William Lewis, Director, Chair and CEO, on July 09, 2026, sold 10,699 shares in Insmed (INSM) for $1,256,084. Following the Form 4 filing with the SEC, Lewis has control over a total of 492,982 common shares of the
REGULATION | Jul 10, 2026, 08:08 PM UTC
L
Insmed Insider Sold Shares Worth $1,352,932, According to a Recent SEC Filing
() -- Martina Flammer, Chief Medical Officer, on July 06, 2026, sold 12,302 shares in Insmed (INSM) for $1,352,932. Following the Form 4 filing with the SEC, Flammer has control over a total of 60,486 common shares of th
REGULATION | Jul 08, 2026, 08:07 PM UTC
L
INSM Appoints New VP
Insmed appoints Samuele Butera as Senior Vice President, General Manager, Global Respiratory
EQUITY | Jun 23, 2026, 11:01 AM UTC